Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:CCCC NASDAQ:CTNM NASDAQ:KLRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.53-7.8%$1.55$1.18▼$2.70$407.20M2.021.65 million shs1.46 million shsCCCCC4 Therapeutics$3.85-7.7%$3.15$1.36▼$4.60$425.68M2.922.92 million shs2.13 million shsCTNMContineum Therapeutics$11.49-6.9%$13.26$3.57▼$16.33$429.57M0.89161,956 shs285,368 shsKLRSKalaris Therapeutics$4.44-4.7%$5.50$2.14▼$11.88$105.64M0.1582,088 shs140,751 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-7.83%-18.18%-10.00%+1.32%-26.79%CCCCC4 Therapeutics-7.67%-11.90%+31.40%+26.64%+150.00%CTNMContineum Therapeutics-6.89%-14.83%-23.09%-17.22%+160.54%KLRSKalaris Therapeutics-4.72%-15.75%-12.25%-54.79%+43.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.53-7.8%$1.55$1.18▼$2.70$407.20M2.021.65 million shs1.46 million shsCCCCC4 Therapeutics$3.85-7.7%$3.15$1.36▼$4.60$425.68M2.922.92 million shs2.13 million shsCTNMContineum Therapeutics$11.49-6.9%$13.26$3.57▼$16.33$429.57M0.89161,956 shs285,368 shsKLRSKalaris Therapeutics$4.44-4.7%$5.50$2.14▼$11.88$105.64M0.1582,088 shs140,751 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-7.83%-18.18%-10.00%+1.32%-26.79%CCCCC4 Therapeutics-7.67%-11.90%+31.40%+26.64%+150.00%CTNMContineum Therapeutics-6.89%-14.83%-23.09%-17.22%+160.54%KLRSKalaris Therapeutics-4.72%-15.75%-12.25%-54.79%+43.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 2.89Moderate Buy$8.75471.90% UpsideCCCCC4 Therapeutics 2.57Moderate Buy$7.75101.30% UpsideCTNMContineum Therapeutics 2.50Moderate Buy$20.0074.06% UpsideKLRSKalaris Therapeutics 2.75Moderate Buy$15.60251.35% UpsideCurrent Analyst Ratings BreakdownLatest KLRS, CTNM, AUTL, and CCCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/14/2026AUTLAutolus Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.005/14/2026CTNMContineum Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$14.00 ➝ $16.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/13/2026KLRSKalaris Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/13/2026KLRSKalaris Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$26.00 ➝ $25.004/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026CCCCC4 Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CTNMContineum Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$75.39M5.40N/AN/A$0.67 per share2.28CCCCC4 Therapeutics$35.95M11.84N/AN/A$2.65 per share1.45CTNMContineum Therapeutics$50M8.59N/AN/A$6.99 per share1.64KLRSKalaris TherapeuticsN/AN/AN/AN/A$4.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$287.53M-$1.09N/AN/AN/A-311.98%-128.59%-46.25%8/11/2026 (Estimated)CCCCC4 Therapeutics-$104.99M-$1.19N/AN/AN/A-297.76%-50.68%-33.22%8/6/2026 (Estimated)CTNMContineum Therapeutics-$59.98M-$1.95N/AN/AN/AN/A-27.09%-25.64%8/4/2026 (Estimated)KLRSKalaris Therapeutics-$43.44M-$2.15N/AN/AN/AN/A-72.78%-43.49%N/ALatest KLRS, CTNM, AUTL, and CCCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AUTLAutolus Therapeutics-$0.29-$0.27+$0.02-$0.27$26.27 million$26.22 million5/12/2026Q1 2026CCCCC4 Therapeutics-$0.2506-$0.20+$0.0506-$0.20$4.42 million$6.15 million5/12/2026Q1 2026KLRSKalaris Therapeutics-$0.52-$0.46+$0.06-$0.46N/AN/A5/5/2026Q1 2026CTNMContineum Therapeutics-$0.55-$0.39+$0.16-$0.39N/AN/A3/27/2026Q4 2025AUTLAutolus Therapeutics-$0.27-$0.34-$0.07-$0.34$23.92 million$24.29 million3/17/2026Q4 2025KLRSKalaris Therapeutics-$0.56-$0.44+$0.12-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/ACTNMContineum TherapeuticsN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A5.805.28CCCCC4 TherapeuticsN/A9.009.00CTNMContineum TherapeuticsN/A38.0038.00KLRSKalaris TherapeuticsN/A12.1912.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%CCCCC4 Therapeutics78.81%CTNMContineum TherapeuticsN/AKLRSKalaris Therapeutics66.05%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%CCCCC4 Therapeutics5.60%CTNMContineum Therapeutics11.30%KLRSKalaris Therapeutics68.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableCCCCC4 Therapeutics150110.57 million104.38 millionOptionableCTNMContineum Therapeutics3137.39 million33.16 millionN/AKLRSKalaris Therapeutics11023.79 million7.59 millionN/AKLRS, CTNM, AUTL, and CCCC HeadlinesRecent News About These CompaniesKalaris Therapeutics (NASDAQ:KLRS) Upgraded to "Hold" at Wall Street ZenJune 6 at 1:43 AM | americanbankingnews.comKalaris Therapeutics Stock Price HistoryMay 30, 2026 | investing.comKalaris Therapeutics (NASDAQ:KLRS) Director Srinivas Akkaraju Acquires 244,300 SharesMay 23, 2026 | insidertrades.comKalaris Therapeutics director Akkaraju’s fund buys $1.18m stockMay 22, 2026 | investing.comKalaris Therapeutics Inc KLRSMay 16, 2026 | morningstar.comMWedbush initiates coverage of Kalaris Therapeutics (KLRS) with outperform recommendationMay 15, 2026 | msn.comKalaris Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 12, 2026 | globenewswire.comMorgan Stanley initiates coverage of Kalaris Therapeutics (KLRS) with overweight recommendationApril 17, 2026 | msn.comKalaris Therapeutics (NASDAQ:KLRS) CAO Sells 1,915 SharesMarch 24, 2026 | insidertrades.comKalaris Reports Full Year 2025 Financial Results and Provides Business UpdatesMarch 17, 2026 | globenewswire.comSrinivas Akkaraju Buys 479,847 Shares of Kalaris Therapeutics (NASDAQ:KLRS) StockFebruary 18, 2026 | insidertrades.comKalaris Therapeutics: Samsara Opportunity fund buys $5m in sharesFebruary 17, 2026 | investing.comKalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual MeetingJanuary 28, 2026 | markets.businessinsider.comWhy Kalaris Therapeutics, Inc.’s (KLRS) Stock Is Up 10.77%January 9, 2026 | aaii.comAKalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 CatalystsDecember 19, 2025 | seekingalpha.comKalaris Therapeutics announces oversubscribed $50 million financingDecember 18, 2025 | msn.comKalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For GrowthDecember 18, 2025 | seekingalpha.comKalaris Therapeutics raises $50M privatelyDecember 18, 2025 | msn.comKalaris Therapeutics price target raised to $26 from $20 at CitizensDecember 18, 2025 | msn.comKalaris Therapeutics announces initial data from TH103 trialDecember 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKLRS, CTNM, AUTL, and CCCC Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.53 -0.13 (-7.83%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.53 0.00 (0.00%) As of 06/5/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.C4 Therapeutics NASDAQ:CCCC$3.85 -0.32 (-7.67%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.84 -0.02 (-0.39%) As of 06/5/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Contineum Therapeutics NASDAQ:CTNM$11.49 -0.85 (-6.89%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$11.52 +0.03 (+0.22%) As of 06/5/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Kalaris Therapeutics NASDAQ:KLRS$4.44 -0.22 (-4.72%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.33 -0.11 (-2.57%) As of 06/5/2026 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
